![]() ![]() It was found that the increased expression of the MRP1 gene was associated with the following subgroups of patients: Non‑smokers vs. A total of 36 clinical studies involving 3,278 patients were included in the study. The quality of methodology, heterogeneities and publication bias of the included articles were also analyzed. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each selected study, with either the fixed‑effects model or the random‑effects model where appropriate. All data from patients with NSCLC who underwent testing for MRP1, by either immunohistochemistry or reverse transcription‑polymerase chain reaction, were extracted and combined for further analysis. ![]() A systematic search was conducted to obtain relevant studies published in English, Chinese and Japanese databases. In the present meta‑analysis, all available published data were combined to provide an updated view on the clinicopathological relevance of MRP1 in patients with NSCLC. ![]() MRP1 is known for its ability to actively decrease intracellular drug concentration, limiting the efficacy of cancer chemotherapy however, data on the clinical relevance of MRP1 is inconclusive. The multidrug resistance‑associated protein 1 (MRP1) gene has been found to be consistently overexpressed in the majority of patients with non‑small cell lung cancer (NSCLC). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |